UPOSBI
LIVE

Serial Number

99817502

Owner

Ipsen Pharma S.A.S.

Attorney

Ben Natter

Filing Date

May 12, 2026

Add to watchlist:

No watchlists yet
View on USPTO

UPOSBI Trademark

Serial Number: 99817502

UPOSBI is a trademark filed by Ipsen Pharma S.A.S. on May 12, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Ipsen Pharma S.A.S. (3 trademarks)

65, quai Georges Gorse
Boulogne Billancourt 92100 , FR

Entity Type: 99

Trademark Details

Filing Date

May 12, 2026

Registration Date

Not Registered

Published for Opposition

September 8, 2026

Goods & Services

Pharmaceutical preparations for use in the diagnosis, treatment, or prevention of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty related diseases or disorders, gynecological disorders, fertility, acromegaly and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, hematological diseases and disorders, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases and disorders, muscle disorders, bone disorders, skeletal disorders, peripheral nervous system disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain; pharmaceutical preparations for aesthetic and therapeutic use, including for the diagnosis, treatment, or prevention of glabellar lines, forehead lines, lateral canthal lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations for skin care

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 8, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 7, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 7, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 7, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 5, 2026 GNRN
NON-FINAL ACTION E-MAILED
Aug 5, 2026 GNRT
NON-FINAL ACTION WRITTEN
Aug 5, 2026 CNRT
ASSIGNED TO EXAMINER
Jul 27, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
May 12, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 12, 2026 NWOS
NEW APPLICATION ENTERED
May 12, 2026 NWAP